These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 36509285)
1. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer. Heiduk M; Plesca I; Glück J; Müller L; Digomann D; Reiche C; von Renesse J; Decker R; Kahlert C; Sommer U; Aust DE; Schmitz M; Weitz J; Seifert L; Seifert AM JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509285 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma. Rupp L; Dietsche I; Kießler M; Sommer U; Muckenhuber A; Steiger K; van Eijck CWF; Richter L; Istvanffy R; Jäger C; Friess H; van Eijck CHJ; Demir IE; Reyes CM; Schmitz M Front Immunol; 2024; 15():1378190. PubMed ID: 38629072 [TBL] [Abstract][Full Text] [Related]
4. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. Farren MR; Sayegh L; Ware MB; Chen HR; Gong J; Liang Y; Krasinskas A; Maithel SK; Zaidi M; Sarmiento JM; Kooby D; Patel P; El-Rayes B; Shaib W; Lesinski GB JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31830001 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells. Mota Reyes C; Teller S; Muckenhuber A; Konukiewitz B; Safak O; Weichert W; Friess H; Ceyhan GO; Demir IE Clin Cancer Res; 2020 Jan; 26(1):220-231. PubMed ID: 31585935 [TBL] [Abstract][Full Text] [Related]
6. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry. Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Dias Costa A; Väyrynen SA; Chawla A; Zhang J; Väyrynen JP; Lau MC; Williams HL; Yuan C; Morales-Oyarvide V; Elganainy D; Singh H; Cleary JM; Perez K; Ng K; Freed-Pastor W; Mancias JD; Dougan SK; Wang J; Rubinson DA; Dunne RF; Kozak MM; Brais L; Reilly E; Clancy T; Linehan DC; Chang DT; Hezel AF; Koong AC; Aguirre AJ; Wolpin BM; Nowak JA Clin Cancer Res; 2022 Dec; 28(23):5167-5179. PubMed ID: 36129461 [TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA-seq reveals characteristics in tumor microenvironment of PDAC with MSI-H following neoadjuvant chemotherapy with anti-PD-1 therapy. Chen K; Ma Y; Liu X; Zhong X; Long D; Tian X; Zheng L; Yang Y Cancer Lett; 2023 Nov; 576():216421. PubMed ID: 37778681 [TBL] [Abstract][Full Text] [Related]
9. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma. Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231 [TBL] [Abstract][Full Text] [Related]
10. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. Zheng L; Ding D; Edil BH; Judkins C; Durham JN; Thomas DL; Bever KM; Mo G; Solt SE; Hoare JA; Bhattacharya R; Zhu Q; Osipov A; Onner B; Purtell KA; Cai H; Parkinson R; Hacker-Prietz A; Herman JM; Le DT; Azad NS; De Jesus-Acosta AMC; Blair AB; Kim V; Soares KC; Manos L; Cameron JL; Makary MA; Weiss MJ; Schulick RD; He J; Wolfgang CL; Thompson ED; Anders RA; Sugar E; Jaffee EM; Laheru DA Clin Cancer Res; 2021 Mar; 27(5):1278-1286. PubMed ID: 33277370 [TBL] [Abstract][Full Text] [Related]
11. The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma. Kawahara K; Takano S; Furukawa K; Takayashiki T; Kuboki S; Ohtsuka M Clin Exp Metastasis; 2022 Apr; 39(2):311-322. PubMed ID: 35000025 [TBL] [Abstract][Full Text] [Related]
12. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC. Yi L; Xu Z; Ma T; Wang C; Wei P; Xiao B; Zhang H; Che N; Liu Z; Han Y Cancer Immunol Immunother; 2024 Apr; 73(6):99. PubMed ID: 38619623 [TBL] [Abstract][Full Text] [Related]
13. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Michelakos T; Cai L; Villani V; Sabbatino F; Kontos F; Fernández-Del Castillo C; Yamada T; Neyaz A; Taylor MS; Deshpande V; Kurokawa T; Ting DT; Qadan M; Weekes CD; Allen JN; Clark JW; Hong TS; Ryan DP; Wo JY; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR J Natl Cancer Inst; 2021 Feb; 113(2):182-191. PubMed ID: 32497200 [TBL] [Abstract][Full Text] [Related]
14. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis. Yoon MS; Lee HS; Kang CM; Lee WJ; Keum J; Sung MJ; Kim SS; Park MS; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Hwang HK; Bang S Gut Liver; 2022 Jan; 16(1):118-128. PubMed ID: 34140428 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Nejati R; Goldstein JB; Halperin DM; Wang H; Hejazi N; Rashid A; Katz MH; Lee JE; Fleming JB; Rodriguez-Canales J; Blando J; Wistuba II; Maitra A; Wolff RA; Varadhachary GR; Wang H Pancreas; 2017 Oct; 46(9):1180-1187. PubMed ID: 28902789 [TBL] [Abstract][Full Text] [Related]
17. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. Gray S; de Liguori Carino N; Radhakrishna G; Lamarca A; Hubner RA; Valle JW; McNamara MG Eur J Surg Oncol; 2022 Jun; 48(6):1198-1208. PubMed ID: 35264307 [TBL] [Abstract][Full Text] [Related]
18. Intraductal pancreatic cancer is less responsive than cancer in the stroma to neoadjuvant chemotherapy. Fujikura K; Hutchings D; Braxton AM; Zhu Q; Laheru DA; Hruban RH; Thompson ED; Wood LD Mod Pathol; 2020 Oct; 33(10):2026-2034. PubMed ID: 32457408 [TBL] [Abstract][Full Text] [Related]
19. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma. Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385 [TBL] [Abstract][Full Text] [Related]
20. Role of biliary stent and neoadjuvant chemotherapy in the pancreatic tumor microbiome. Nalluri H; Jensen E; Staley C BMC Microbiol; 2021 Oct; 21(1):280. PubMed ID: 34656097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]